Telehealth Treatment for Opioid Use Disorders

NCT05832879 | Completed DMC

• 2 other identifiers: 20000344141R61DA057675-01
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

Conditions

Opioid Use Disorder

Keywords

Harm Reduction; Medication for Opioid Use Disorder

Outcome Measures

Primary Outcomes (1)

• Attendance for MOUD

  Overall attendance will be measured by attendance (yes or no) at the first buprenorphine appointment within 30 days of referral.

  Up to 30 Days

Secondary Outcomes (3)

• Engagement with MOUD

  Up to 90 days

• Overdose Events at 30 Days

  Up to 30 days

• Overdose Events at 90 Days

  Up to 90 days

Study Arms (1)

OUD Telehealth Platform

EXPERIMENTAL

Participants will be assigned to receive the OUD Telehealth Platform, which will be delivered remotely by research staff.

Behavioral: OUD Telehealth Platform

Interventions

OUD Telehealth Platform BEHAVIORAL

The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users

OUD Telehealth Platform

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Can speak, read and write in English
• Provision of signed and dated informed consent form
• Have a history of at least one opioid overdose
• Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
• Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
• Can provide a working email address OR be willing to create one

You may not qualify if:

• Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
• Pregnancy
• Known current suicide risk based on participant self-report
• On parole or incarcerated at time of enrollment based on participant self-report

Sponsors & Collaborators

• Yale University: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

Yale School of Medicine

New Haven, Connecticut, 06520, United States

Location

Related Publications (1)

• Canty T, S Sabounchi N, Heimer R, Pantalon M, Ryus C, Buchanan L, Grewal M, Maffei J, D'Onofrio G, Heckmann R. Increasing timely access to evidence-based treatment for opioid use disorder using novel digital health and system dynamics modelling approaches: a study protocol. BMJ Open. 2025 Nov 4;15(11):e102796. doi: 10.1136/bmjopen-2025-102796.

  PMID: 41193189 DERIVED

MeSH Terms

Conditions

Opioid-Related Disorders; Harm Reduction

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Behavior

Study Officials

• Rebekah Heckmann, MD, MPH, MPA

  Yale University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2023
• First Posted: April 27, 2023
• Study Start: May 1, 2024
• Primary Completion: July 24, 2025
• Study Completion: July 24, 2025
• Last Updated: October 6, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share
• Time Frame: Following the close of the study and final reporting to funder.

Locations

US (1)